Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312201 | 0.87 | KCNH2 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL18998989 | 0.83 | — | — | |
| SCHEMBL16248159 | 0.82 | KDM4E (0.37) | NOS3NOS1NOS2 | |
| SCHEMBL830187 | 0.76 | CYP1A2 (0.37) | NOS3NOS1NOS2 | |
| SCHEMBL25987002 | 0.74 | SORD (0.47) | — | |
| Ammonia Solution, Strong SCHEMBL28652832 | 0.74 | CYP1A2 (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL12656586 | 0.74 | KCNH2 (0.48) | NOS1NOS2 | |
| SCHEMBL12314661 | 0.72 | NOS3 (0.47) | NOS3NOS1NOS2 | |
| SCHEMBL27592765 | 0.72 | KDM4E (0.42) | NOS3NOS1NOS2 | |
| Ammonia Solution, Strong SCHEMBL11451734 | 0.72 | CYP1A2 (0.35) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | NOS3 2604/4885NOS1 3975/4885NOS2 3709/4885 |
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | NOS3 2604/4885NOS1 3975/4885NOS2 3709/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | NOS3 4257/4885NOS1 4137/4885NOS2 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.